{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:40:03Z","timestamp":1765827603628,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T00:00:00Z","timestamp":1502928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.vaccine.2017.08.029","type":"journal-article","created":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T08:45:46Z","timestamp":1503132346000},"page":"179-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine"],"prefix":"10.1016","volume":"36","author":[{"given":"Myron J.","family":"Levin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike K.","family":"Buchwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon E.","family":"Stek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoran","family":"Popmihajlov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2017.08.029_b0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cger.2016.02.011","article-title":"Herpes Zoster","volume":"32","author":"Schmader","year":"2016","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.vaccine.2017.08.029_b0010","first-page":"341","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2017.08.029_b0015","unstructured":"ZOSTAVAX\u00ae (Zoster Vaccine Live) [Package insert]. Merck & Co., Inc., Whitehouse Station, NJ 08889, USA, January 26, 2017. Available at: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zostavax\/zostavax_pi2.pdf."},{"issue":"33","key":"10.1016\/j.vaccine.2017.08.029_b0020","first-page":"729","article-title":"Centers for disease control and prevention: update on recommendations for use of herpes zoster vaccine","volume":"63","author":"Hales","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"10.1016\/j.vaccine.2017.08.029_b0025","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1532-5415.2010.03021.x","article-title":"Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults","volume":"58","author":"Schmader","year":"2010","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.vaccine.2017.08.029_b0030","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jama.2010.1983","article-title":"Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease","volume":"305","author":"Tseng","year":"2011","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.vaccine.2017.08.029_b0035","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2017.08.029_b0040","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2017.08.029_b0045","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.029_b0050","unstructured":"European Medicines Agency: Summary of Product Characteristics for ZOSTAVAX\u2122, January 26, 2017. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000674\/WC500053462.pdf."},{"issue":"5","key":"10.1016\/j.vaccine.2017.08.029_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6505a1","article-title":"Prevention and control of seasonal influenza with vaccines","volume":"65","author":"Grohskopf","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2017.08.029_b0060","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/irv.12258","article-title":"Estimates of mortality attributable to influenza and RSV in the United States during 1997\u20132009 by influenza type or subtype, age, cause of death, and risk status","volume":"8","author":"Matias","year":"2014","journal-title":"Influenza Other Respir Viruses"},{"issue":"11","key":"10.1016\/j.vaccine.2017.08.029_b0065","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.292.11.1333","article-title":"Influenza-associated hospitalizations in the United States","volume":"292","author":"Thompson","year":"2004","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.vaccine.2017.08.029_b0070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.289.2.179","article-title":"Mortality associated with influenza and respiratory syncytial virus in the United States","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2017.08.029_b0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/irv.12318","article-title":"Retrospective public health impact of a quadrivalent influenza vaccine in the United States","volume":"9","author":"Cr\u00e9pey","year":"2015","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"10.1016\/j.vaccine.2017.08.029_b0080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4161\/hv.8.1.17623","article-title":"The rationale for quadrivalent influenza vaccines","volume":"8","author":"Ambrose","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.vaccine.2017.08.029_b0085","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1532-5415.2007.01397.x","article-title":"Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older","volume":"55","author":"Kerzner","year":"2007","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"10.1016\/j.vaccine.2017.08.029_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6611a1","article-title":"Surveillance of vaccination coverage among adult populations \u2013 United States, 2015","volume":"66","author":"Williams","year":"2017","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2017.08.029_b0095","unstructured":"Fluzone\u00ae Quadrivalent (Influenza Vaccine) [Package insert]. Sanofi Pasteur, Swiftwater, PA 18370, USA, January 26, 2017. Available at: https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm356094.pdf."},{"issue":"12","key":"10.1016\/j.vaccine.2017.08.029_b0100","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/jmv.20754","article-title":"The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zostervirus (VZV) antibody detection","volume":"78","author":"Hammond","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2017.08.029_b0105","unstructured":"WHO Global Influenza Surveillance Network: Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza, January 26, 2017. Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/44518\/1\/9789241548090_eng.pdf."},{"issue":"4","key":"10.1016\/j.vaccine.2017.08.029_b0110","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2307\/2531734","article-title":"Models for longitudinal data: a generalized estimating equation approach","volume":"44","author":"Zeger","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2017.08.029_b0115","doi-asserted-by":"crossref","unstructured":"Levin MJ, Oxman MN, Johnson GR, Zhang JH, Hayward AR, Weinberg A. Immune response to a refrigerator-stable zoster vaccine. Clin Vaccine Immunol 2009;16(9):1381; author reply-2.","DOI":"10.1128\/CVI.00338-08"},{"key":"10.1016\/j.vaccine.2017.08.029_b0120","unstructured":"FDA Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines, January 26, 2017. Available at: http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm074794.htm."},{"issue":"2","key":"10.1016\/j.vaccine.2017.08.029_b0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2017.08.029_b0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1750-2659.2011.00268.x","article-title":"Quantitative review of antibody response to inactivated seasonal influenza vaccines","volume":"6","author":"Seidman","year":"2012","journal-title":"Influenza Other Respir Viruses"},{"issue":"6","key":"10.1016\/j.vaccine.2017.08.029_b0135","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2017.08.029_b0140","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.029_b0145","unstructured":"FDA Guidance for Industry: Non-Inferiority Clinical Trials. 2010. Available at: http:\/\/www.fdanews.com\/ext\/resources\/files\/archives\/n\/NoninferiorityGuidance.pdf January 26, 2017."},{"issue":"12","key":"10.1016\/j.vaccine.2017.08.029_b0150","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.vaccine.2015.01.072","article-title":"Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials","volume":"33","author":"Donken","year":"2015","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2017.08.029_b0155","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jiu279","article-title":"Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve","volume":"210","author":"Gilbert","year":"2014","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2017.08.029_b0160","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/infdis\/jit342","article-title":"Varicella-zoster virus-specific antibody responses in 50\u201359-year-old recipients of zoster vaccine","volume":"208","author":"Levin","year":"2013","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2017.08.029_b0165","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/infdis\/jiv480","article-title":"Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults","volume":"213","author":"Levin","year":"2016","journal-title":"J Infect Dis."},{"issue":"23","key":"10.1016\/j.vaccine.2017.08.029_b0170","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1016\/j.vaccine.2010.03.067","article-title":"Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence","volume":"28","author":"Song","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2017.08.029_b0175","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/aje\/154.2.155","article-title":"Influenza vaccine effectiveness among elderly nursing home residents: a cohort study","volume":"154","author":"Monto","year":"2001","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2017.08.029_b0180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1447-0594.2010.00641.x","article-title":"Immune response to influenza vaccine in the elderly: association with nutritional and physical status","volume":"11","author":"Sagawa","year":"2011","journal-title":"Geriatr Gerontol Int"},{"issue":"5","key":"10.1016\/j.vaccine.2017.08.029_b0185","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.vaccine.2012.11.074","article-title":"Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults","volume":"31","author":"Greenberg","year":"2013","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17310964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17310964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:25:03Z","timestamp":1759400703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17310964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0264410X17310964"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.029","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc and The Authors.  Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}